Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + anlotinib as second-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
ChiCTR2000037517Phase 2Recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Henan Provincial People's Hospital. Primary endpoint: overall survival. Started Sep 2020; status: recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2000037517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037517.